Joanne counsels global clients on various regulatory and distribution-related considerations related to bringing a new FDA-regulated product to market and how to ensure continued compliance after a product is commercialized, including with respect to advertising and promotion. She also advises on the business impact of new US federal and state actions that affect regulated products, such as drugs, biologics, regenerative medicine products, foods, cosmetics, and medical devices, including in vitro diagnostics, lab tests, and mobile medical applications.
Her strategic counseling and compliance support work reaches into all aspects of FDA-regulated companies’ operations, from regulatory exclusivity considerations to arrangements with third-party distributors. Joanne’s regulatory and compliance work include:
- Determining regulatory status of novel products
- Pre-market and post-market compliance requirements for various regulated products
- Restrictions on advertising and product sampling, as well as legal obligations associated with the use of social media influencers or patient ambassadors to promote medical and consumer-directed products
- State licensing schemes for prescription drug and medical device manufacturers and distributors
- Compliance with prescription drug compounding regulations
- Review and approval of various types of policies and procedures for facilities that manufacture or distribute regulated products
- Advising on or preparing clients’ written submissions to FDA requests for comments or rulemaking activities
- FDA’s current requirements for importing and exporting regulated products
- Food safety and labeling advice for food, including dietary supplements and functional foods
Joanne frequently works with clients to develop and implement their responses to common FDA actions, such as warning letters and inspectional reports (the “Form 483”). She has also been involved in advising and helping clients respond to Federal Trade Commission investigations related to product advertising and requests for substantiation of certain promotional claims.
As an FDA regulatory specialist, Joanne assists the Mintz Corporate team by performing regulatory due diligence as part of potential mergers and acquisitions that involve regulated companies, and she often works in conjunction with the firm’s Intellectual Property attorneys to ensure that patent and regulatory activities are strategically aligned. She also collaborates regularly with Mintz attorneys who negotiate royalty monetization transactions and who defend false advertising or product liability litigation brought against FDA-regulated businesses. Although the day-to-day work for clients may be different, the common thread that she enjoys most is helping companies (both startup and established) bring their products to market — without heightened risks of enforcement actions as a result of non-compliance with sometimes opaque regulatory requirements.
Prior to joining Mintz, Joanne was an attorney in the food and drug practice in the DC office of another law firm.
Joanne is an editor of and frequent contributor to the firm's health care Viewpoints.
Experience
- Serves as regulatory specialist on royalty and revenue interest financing transactions led by Mintz Corporate and Intellectual Property attorneys on behalf of biopharmaceutical clients.
- Successfully represented a foreign API manufacturer in front of the FDA with respect to a sensitive product recall and US removal action.
- Represented a diagnostic developer during an FDA investigation into its alleged distribution of an unauthorized test for COVID-19 and subsequent recall activities.
- Supported Mintz Corporate team in negotiating and executing the sale of a client’s FDA Priority Review Voucher to another party for over $100 million.
- Negotiated the release of consumer goods by FDA on behalf of a retailer client following the agency’s erroneous conclusion that the shipments contained laser components that did not comply with US law, thereby leading to their detention at the port of entry.
- Counseled a nationally recognized health system regarding the construction of advertising claims for various services involving regenerative medicine-based therapeutic procedures.
- Served as FDA specialist and regulatory team leader on a client’s complex bid for a bankrupt pharmaceutical company’s US and European drug-related assets, including marketing authorizations and distribution permits.
- Handled regulatory due diligence and related contractual negotiations for two acquisitions of independent testing laboratories by a global client.
- Worked with several Mintz clients operating in non-FDA regulated industries to determine how to manufacture and distribute face shields, face masks, and alcohol-based hand sanitizers in compliance with FDA’s enforcement discretion policies during the COVID-19 pandemic, including by providing promotion and labeling advice.
- Guided clients developing COVID-19 diagnostic or serological tests on various promotional risks and regulatory obligations both before and after they secured Emergency Use Authorizations from FDA that allowed the test to be distributed and used in the US.
- Prepared a Breakthrough Designation Request on behalf of a therapeutic developer client and helped another client secure Orphan Drug Designation for its innovative drug product.
- Participates in the Medical, Legal, and Regulatory (MLR) Committees that are engaged in promotional review activities on behalf of multiple clients with recently approved new drugs and biologics.
- Negotiated with FDA on behalf of a cosmetic client when a large shipment of imported products was detained by Customs and Border Protection due to non-compliant labeling and assisted company in developing plans for reconditioning the products.
- Counseled a cosmetic company on its response to an FDA Warning Letter related to the use of drug claims to promote cosmetic products and then assisted in the company’s implementation of internal processes and procedures to avoid similar issues in the future.
- Represented an innovative beverage company with a national profile on FDA compliance issues, labeling, promotional activities, and distribution agreements.
- Served as FDA/FTC regulatory counsel on multiple private equity acquisitions of consumer product companies with high-end, global skincare and haircare brands.
viewpoints
FDA in Flux — October 2026 Newsletter
October 19, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli, Madison Castle, Grace Wang
The October 2026 edition of FDA in Flux highlights the latest developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.
FDA in Flux — September 2026 Newsletter
September 17, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli, Madison Castle, Grace Wang
Key FDA updates on generative AI, medical product user fees, SEC coordination, GLP-1 drug shortages, and the future of diagnostic testing.
FDA in Flux — August 2026 Newsletter
August 13, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli, Madison Castle, Grace Wang
The August 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for the medical, life sciences, and consumer product sectors.
FDA’s Advisory Committee Votes on Peptides: What It Does and Doesn’t Do
July 29, 2026 | Blog | By Joanne Hawana
A hastily reassembled Pharmacy Compounding Advisory Committee (PCAC) held meetings on July 23 and 24, 2026 to consider whether seven unapproved peptides should be included on an affirmative list of bulk ingredients that can be used by compounding pharmacies operating under the Food, Drug, & Cosmetic Act’s (FD&C Act) Section 503A (503A compounders). A second PCAC meeting to discuss an additional five peptides is expected to be scheduled in February 2027. In close votes over the course of July’s two-day meeting, the PCAC members recommended that BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax be added to the 503A affirmative list. They voted against the addition of emideltide.
FDA in Flux — June 2026 Newsletter
June 17, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli
The June 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.
FDA in Flux — May 2026 Newsletter
May 19, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli, Raymond Vanderhyden
The May 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.
FDA in Flux — April 2026 Newsletter
April 16, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli
The April 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.
FDA in Flux — March 2026 Newsletter
March 18, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli
The March 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.
FDA in Flux — February 2026 Newsletter
February 23, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli
The February 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.
FDA in Flux — January 2026 Newsletter
January 22, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli
The January 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.
News & Press
Mintz advised the placement agents in connection with First Tracks Biotherapeutics’ $200 million private placement of common stock.
Mintz Advises on Verastem Oncology’s $250 Million Underwritten Offering
October 15, 2026|
Mintz Advises on Atrium Therapeutics’ $50 Million Private Placement
October 12, 2026|
Mintz Advises on Edesa Biotech’s $25 Million Public Offering
August 25, 2026|
Mintz Advises Saltair in Sale of Majority Stake to TSG Consumer
August 13, 2026|
Mintz Advises on uniQure’s $259 Million Public Offering
June 25, 2026|
Mintz Advises on Eupraxia Pharmaceuticals $63.2 Million Public Offering
February 27, 2026|
US Signals Crackdown on Compounded Weight-Loss Drugs; Hims Shares Tumble
February 6, 2026|
Mintz Advises on Fulcrum Therapeutics' $175 Million Public Offering
December 16, 2025|
Mintz Advises on Protara Therapeutics' $75 Million Public Offering
December 16, 2025|
Mintz Advises on Capricor Therapeutics’ $150 Million Public Offering
December 10, 2025|
Lawyers Adapt to Crop of New FDA Pilots
December 2, 2025|
Mintz Advises on Verastem Oncology’s $103 Million Public Offering
November 21, 2025|
Mintz Advises on MoonLake Immunotherapeutics’ $75 Million Offering
November 12, 2025|
FDA’s Deceptive Drug Ad Focus Leaves Telehealth Sites Guessing
October 14, 2025|
Mintz Advises VMG on Partnership with Scenthound
October 9, 2025|
Mintz Advises on uniQure's $345 Million Public Offering
September 30, 2025|
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025|
Mintz Advises PHLUR on Acquisition by TSG Consumer
July 29, 2025|
HHS Restructuring and Workforce Reductions
June 1, 2025|
Super Bowl Ad Selling Weight Drug Shows Wild West of Copycats
February 7, 2025|
TikToker Drug Ads Spark Demands for FDA to Clarify Its Authority
February 16, 2024|
Digging Into The Debate On FDA's Proposed Lab Test Rule
January 3, 2024|
TikTokers Put Consumers at Risk as Drug Ads Go Unchecked by FDA
December 14, 2023|
Mintz Forms Pioneering Women’s Health & Technology Practice
March 9, 2023|
Mintz Debuts 'Femtech' Practice For Life Science Clients
March 9, 2023|
Pared-Down FDA-Fee Bill Moving With CR
September 28, 2022|
Charting A Year Of The Biggest COVID Scams Cited By FDA
March 15, 2021|
Mintz Advises NexImmune in its Upsized $126.5 Million IPO
February 17, 2021|
Legal Risks of Employer-Sponsored Covid-19 Workplace Vaccination Clinics
February 12, 2021|
User Fees Will Be A Focus For Senate HELP, No Matter Who’s In Charge
November 5, 2020|
COVID-19: Regulators Confronted with Scourge of ‘Fake Cures’
September 29, 2020|
Introduction to the Due Diligence Process
July 27, 2020|
What FDA Has Done So Far In Response To COVID-19
April 1, 2020|
Mintz Promotes Eleven Attorneys to Member
May 10, 2019|
FDA Finally Hitting Sweet Spot With Off-Label Oversight
November 21, 2018|
MODERN Labeling Act Needs Liability Protection for Generics
November 14, 2018|
Cosmetic Companies Must Plan For New Regulation
December 14, 2017|
But What About Food? FDA Director Scott Gottlieb’s 4-month Scorecard
September 14, 2017|
5 Ways Trump Could Change Food Safety Compliance
April 26, 2017|
New FDA Enforcement Stats Show Shifting Targets
February 13, 2017|
Will FDA Adverse Event Data Release Mean More Lawsuits?
January 18, 2017|
The FDA targeted DTC, video, unapproved drug promotion in 2016
January 18, 2017|
Health Care Enforcement Review And 2017 Outlook: Part 1
January 13, 2017|
FDA Sticks to Its Naming Plan for Biologics and Biosimilars
January 13, 2017|
Mintz Attorney Joanne S. Hawana to Speak at 2016 TEDCO Entrepreneur Expo
November 2, 2016|
Why FSMA collaboration is the new normal in food transportation
November 1, 2016|
Providers, Pharmacists Call for Earlier FDA Guidance on Biosimilars
October 24, 2016|
Food Safety Regulations Will Affect California Tort Law
July 13, 2016|
GE Salmon Sets Stage For Future GMO Labeling Regime
June 27, 2016|
Food Companies Are Hedging Their Bets With GMO Labeling
April 25, 2016|
podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025 | Podcast | By Bridgette Keller, Joanne Hawana , Benjamin Zegarelli
Of Counsel Bridgette Keller is joined by Joanne Hawana, Ben Zegarelli, and John Daley, as they offer advice for navigating communications with the FDA.
Health Law Diagnosed – New Year's Gratitude
February 3, 2025 | Podcast | By Bridgette Keller, Alison H. Peters, Samantha Kingsbury, Theresa Carnegie, Joanne Hawana , Abdie Santiago, Stephnie John, Pamela Polevoy, Karen Lovitch , Jean D. Mancheno, Deborah Daccord, Rachel A. Alexander, Jane Haviland, David Gilboa, Kathryn Edgerton, Hassan Shaikh, Madison Castle, Laurence Freedman, Priyanka Amirneni, Samantha Hawkins, Tara E. Dwyer, Rachel Yount, Sophia Temis, Xavier Hardy
Host Of Counsel Bridgette Keller invites the Mintz Health Law team to reflect on what they’re grateful for as they prepare for the year ahead. Hear from a dynamic group of Members, Of Counsel, and Associates as they share their perspectives on what’s coming up over the horizon.
Health Law Diagnosed – A Discussion on the Regulatory Requirements for LDTs
March 7, 2024 | Podcast | By Bridgette Keller, Joanne Hawana , Benjamin Zegarelli
In this episode of Health Law Diagnosed, host Bridgette Keller is joined by Mintz Health Law attorneys Joanne Hawana and Benjamin Zegarelli to discuss the FDA’s long-awaited proposed rules that actively regulate laboratory developed tests (LDTs).
Mintz Health Law: What We Are Grateful For
January 11, 2023 | Podcast | By Bridgette Keller
Bridgette Keller speaks with the Mintz Health Law team about what they are grateful for as they look back on a year of client service, mentorship, and working together as a team.
Health Law Diagnosed — Mintz’s 2022 Health Law New Year’s Resolutions
January 12, 2022 | Podcast | By Bridgette Keller
Health Law Diagnosed — Hot Topics in FDA Regulation and Enforcement
May 12, 2021 | Podcast | By Joanne Hawana , Benjamin Zegarelli
Events & Speaking
Bridging US Market Access in Bio Sciences and Cosmetics: From Partnership to Deployment
Korean-American Professional Association in Life Sciences, California (KAPAL CA)
Virtual Webinar
FDA 101: A Guide to Agency Structure, Jurisdiction, Regulation, and Enforcement
American Conference Institute FDA Bootcamp
New York City Bar Association (42 W 44th St, New York, NY 10036)
Free Drug Programs and Cost-Sharing Assistance: Anti-Kickback Statute Considerations
Drug Information Association, Regulatory Affairs Community AdPromo Working Group
Virtual Webinar
Drug Information Association (DIA): Advertising and Promotion Regulatory Affairs Conference
Sheraton Pentagon City Hotel Arlington, VA
Guide to Advertising for Life Sciences Companies: Insights from Legal and Business Perspectives
Association of Corporate Counsel San Francisco
Online Event
The Food and Drug Administration (FDA): Series Spanning Key Topics
Regulation of Foods & Cosmetics
US Regulation of Advertising, Promotion and Labeling for Medical Devices
Regulatory Affairs Professionals Society (RAPS)
DIA Advertising and Promotion Regulatory Affairs Conference
Drug Information Association (DIA)
Arlington, VA
Pro Bono in a Virtual Age: A conversation with KIND, Legal Aid Society, and Bread for the City
Kids In Need Of Defense (KIND)
Online Event
US Regulation of Advertising, Promotion and Labeling for Medical Devices
Regulatory Affairs Professional Society (RAPS)
Online Event
Regenerative Medicine: Regulatory, Legal, and Compliance Challenges for Cell and Gene Therapies
Food and Drug Law Institute
Online Event
Mandatory or Voluntary Workplace Vaccination – Guidance for Employers
This is an online event.
Food and Drug Law Institute Annual Conference
FDA’s Amended Intended Use Regulation – Has It Finally Hit the Sweet Spot?
Online Event
DIA Advertising and Promotion Regulatory Affairs Conference
Engaging with Patients to Diversify Advertising and Promotional Activities
Online Event
Everything Life Sciences Companies Need to Know to Navigate the COVID-19 Pandemic
View the Webinar Recording
Introduction to Biologics and Biosimilars Law and Regulation Course Presented by FDLI
Regenerative Medicine Advanced Therapies (RMATs)
ELabs NYC
Planning for Success: Integrating Product Development with Intellectual Property and Regulatory Strategies
New York, NY
Six-Month Assessment: The Impact of Gottlieb’s Departure on FDA Priorities
Mintz, 3580 Carmel Mountain Road | Suite 300, San Diego, CA
RAPS Virtual Program: US Regulation of Advertising, Promotion, and Labeling for Medical Devices (2-Part Series)
Navigating Federal Trade Commission (FTC) Requirements for Medical Products
Food and Drug Law Institute Annual Conference
Regenerative Medicine, Gene Therapies, and FDA Regulation
Washington, DC
FDLI's Introduction to Drug Law and Regulation Course
Regulation of Over-the-Counter OTC Drugs
Lake County, Illinois
ELabs NYC
Planning for Success: Integrating Product Development with Intellectual Property and Regulatory Strategies
New York, NY
Drug Compounding Post-DQSA: Emerging Regulatory Challenges & Business Opportunities
Mintz, One Financial Center, 38A, Boston, MA 02111
The 9th Annual Advertising and Promotion of Medical Devices Conference
FTC’s Authority Applied to the Regulation of Medical Devices
The Madison Hotel, Washington, D.C.
Compounding Under Sections 503A and 503B: Distinctions, Limitation, Liabilities, and Compliance
FDANEWS
Webinar
Publications
- Co-author, The Grocer Will Fill Your Order Now: Modernizing Online Food Shopping Becomes a Priority for Federal Agencies, Update Magazine (Fall 2023).
Recognition & Awards
William P. Cunningham Award for Achievement and Service to the School of Law, University of Maryland (2007)
Manuscripts editor, The Journal of Health Care Law and Policy (Vol. 10)
Legal 500 United States: Recognized for Healthcare: Service Providers (2020); Life Sciences (2021)
JD Supra: Top Author, Readers' Choice Awards – Life Sciences (2021)
Mondaq: Thought Leadership Award Winner, Autumn 2025
Pro Bono Advocate of the Year Award, Kids In Need of Defense (KIND) (2023)
Involvement
- Member, Food and Drug Law Institute (FDLI)
- Member, FDLI Audit Committee
- Member, Drug Information Association (DIA)
- Member, American Bar Association (ABA), and ABA Health Law Section
- Member, American Health Lawyers Association (AHLA), and AHLA Life Sciences Practice Group
- Member, Mintz Pro Bono Committee
- Past Chair, FDLI Publications Committee
- Past Chair, FDLI Primer Committee
- Past Chair, FDLI Update Magazine Editorial Advisory Board
